Antiverse secures £7m Series A led by Soulmates Ventures for AI-designed antibodies targeting undruggable diseases

Antiverse develops therapeutic antibodies designed using machine learning and built in its own laboratories. It generates and tests antibody candidates against difficult disease targets, including membrane proteins, for pharmaceutical and foundation partners.